Outcomes
toxicity
SECONDARY
The primary endpoint was to determine the RP2D of ulixertinib in combination with GnP. The secondary endpoints included safety and toxicity profile, biochemical and radiographic response, progression-free survival (PFS), and overall survival (OS) for patients treated with ulixertinib in combination with GnP.